|
Volumn 21, Issue 5, 2006, Pages 1444-1445
|
Pegylated interferon and ribavirin in haemodialysis patients [5]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ERYTHROPOIETIN;
IRON;
PEGINTERFERON ALPHA2A;
PEGINTERFERON ALPHA2B;
PROTEINASE INHIBITOR;
RIBAVIRIN;
VIRUS RNA;
ANEMIA;
CLINICAL TRIAL;
DRUG BLOOD LEVEL;
DRUG CLEARANCE;
DRUG DOSE REGIMEN;
DRUG METABOLISM;
DRUG RESPONSE;
DRUG TOLERABILITY;
FATIGUE;
FLU LIKE SYNDROME;
GENOTYPE;
HEMODIALYSIS PATIENT;
HEPATITIS C;
HUMAN;
KIDNEY FAILURE;
LETTER;
MYALGIA;
NONHUMAN;
PRIORITY JOURNAL;
COHORT STUDIES;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
DRUG THERAPY, COMBINATION;
FEMALE;
FOLLOW-UP STUDIES;
HEPATITIS C, CHRONIC;
HUMANS;
INTERFERON ALFA-2B;
KIDNEY FAILURE, CHRONIC;
POLYMERASE CHAIN REACTION;
RENAL DIALYSIS;
RIBAVIRIN;
RISK ASSESSMENT;
RNA, VIRAL;
TREATMENT OUTCOME;
|
EID: 33646166212
PISSN: 09310509
EISSN: 14602385
Source Type: Journal
DOI: 10.1093/ndt/gfl072 Document Type: Letter |
Times cited : (12)
|
References (6)
|